In Brief

Acetylcysteine for Patients Requiring Mucus Secretion Clearance: A Review

Key Messages
- The clinical effectiveness and safety of acetylcysteine for mucus secretion clearance was unclear because of sparse evidence. High-quality studies are needed.
- No clinical effectiveness studies were identified for acetylcysteine use in patients with neuromuscular disorder requiring mucus secretion clearance.
- No relevant studies comparing the effectiveness of oral acetylcysteine compared with inhaled acetylcysteine were identified.
- High-quality studies comparing acetylcysteine with other pharmacologic treatments for mucus secretion clearance are needed.
- Three guidelines recommend using oral acetylcysteine for patients with chronic obstructive pulmonary disease (these recommendations were weak or conditional, and based on low- or moderate-quality evidence).
- One guideline does not provide any recommendation for the use of acetylcysteine because of insufficient evidence, and two guidelines recommend against its use for specific clinical scenarios (the strength of the recommendations was not reported).

Context
Mucus secretions are a defence mechanism of the lung. The mucus traps particles and pathogens inhaled in the air and is then cleared by airflow and ciliary hairs. Mucus secretions in people with lung disease can be thick and sticky, and therefore not easily cleared. Drug treatments for impaired mucus secretion clearance include isotonic saline, hypertonic saline, dornase alpha, and acetylcysteine.

Technology
Acetylcysteine is used as a treatment option in various conditions where there are problems with clearance of lung mucus secretions, such as chronic obstructive pulmonary disease and chronic bronchitis, and in patients who are intubated or post-operative.

Issue
Acetylcysteine is used in practice to aid in the clearance of mucus from the lungs. A review of the comparative clinical effectiveness and safety, and a review of evidence-based guidelines, will help to inform decisions regarding the use of acetylcysteine for mucus secretion clearance in practice for various patient populations. Additionally, a review of the clinical effectiveness of treatment with nebulized acetylcysteine versus oral acetylcysteine may provide direction on formulation selection in practice.

Methods
A limited literature search was conducted of key resources, and titles and abstracts of the retrieved publications were reviewed. Full-text publications were evaluated for final article selection according to predetermined selection criteria (population, intervention, comparator, outcomes, and study designs). For the report regarding acetylcysteine for patients with neuromuscular disorders who require mucus secretion clearance, a limited literature search was performed; a reference list was compiled of articles potentially meeting the pre-specified inclusion criteria.

Results
Clinical evidence based on 12 publications — five systematic reviews, one randomized controlled trial, and six evidence-based guidelines — was summarized from three Rapid Response reports.

Clinical effectiveness data were sparse. One randomized controlled trial, included in a systematic review on hospitalized patients with acute lung disease, compared acetylcysteine with isotonic saline. This trial reported improvement in coughing out mucus, mucus thickness, and oxygenation with acetylcysteine; however, these results were either not statistically significant or statistical significance was not reported. The Rapid Response reference list on acetylcysteine for patients with neuromuscular disorder who require mucus secretion clearance did not identify any relevant clinical effectiveness studies.
Safety-related outcomes for the comparison of acetylcysteine with placebo — such as hospitalization, atelectasis (complete or partial collapse of the lung), and mortality — were sparsely reported and the results were variable.

Three guidelines recommend the use of acetylcysteine for chronic obstructive pulmonary disease. One guideline does not provide any recommendation because of insufficient evidence; one guideline recommends against the use of acetylcysteine for acute cough; and the last guideline recommends against the use of aerosolized acetylcysteine for patients who are hospitalized, or those with neuromuscular disease, respiratory muscle weakness, or impaired cough.

Read more about CADTH and this topic at:
cadth.info/310K7NI
cadth.info/2K9hlne
cadth.info/2vQyWNd

Questions or comments about CADTH or this tool?

Online: cadth.ca
Email: requests@cadth.ca
Twitter: @CADTH_ACMTS
New at CADTH Newsletter: cadth.ca/subscribe

DISCLAIMER
This material is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose; this document should not be used as a substitute for professional medical advice or for the application of professional judgment in any decision-making process. Users may use this document at their own risk. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not guarantee the accuracy, completeness, or currency of the contents of this document. CADTH is not responsible for any errors or omissions, or injury, loss, or damage arising from or relating to the use of this document and is not responsible for any third-party materials contained or referred to herein. Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada’s provincial or territorial governments, other CADTH funders, or any third-party supplier of information. This document is subject to copyright and other intellectual property rights and may only be used for non-commercial, personal use or private research and study.